New: Introducing the Finviz Futures Map

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Verona Pharma Plc ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Verona Pharma Plc ADR

Latest News

9 hours	Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? ALKS Zacks
Sep-09	RARE Reports Positive Long-Term Data From Metabolic Disorder Study KNSA Zacks
Sep-08	Health Care Roundup: Market Talk ALKS The Wall Street Journal
Sep-08	Here's Why Exelixis (EXEL) is a Strong Momentum Stock EXEL Zacks
Sep-08	Takeda and Alkermes share OX2R drug data for narcolepsy ALKS Clinical Trials Arena
Sep-08	Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 ALKS PR Newswire
Sep-06	Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D EXEL Insider Monkey
Sep-05	Exelixis, Inc. (EXEL): A Bull Case Theory EXEL Insider Monkey
Sep-04	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results KNSA Zacks
Sep-04	Immunocore to present at upcoming investor conferences IMCR GlobeNewswire
Sep-03	Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue? ALKS Zacks
Sep-03	Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results KNSA Zacks
Sep-03	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol KNSA Zacks
Sep-03	Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why KNSA Zacks
Sep-02	Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA? KNSA Zacks

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.